Forge Biologics Announces Regulatory Updates from FDA and EMA, Accelerating Manufacturing and Clinical Trial Momentum
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced that it has received additional designations and regulatory feedback from the European Medicines Agency (EMA) and the U.S. Food & Drug Administration (FDA), advancing the manufacturing capabilities for its own and clients’ AAV gene therapies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005324/en/
Forge GMP technician at The Hearth (Photo: Business Wire)
The EMA has granted orphan designation for the company’s clinical-stage gene therapy FBX-101 for the treatment of patients with Krabbe disease. FBX-101 is a first-in-human potential treatment utilizing a systemically administered adeno-associated virus (AAV) to deliver the correct version of the faulty gene responsible for an abnormality in patients with Krabbe disease, a rare and fatal genetic disorder. FBX-101 previously received Orphan Drug and Rare Pediatric Disease Designations from the FDA earlier this year.
“FBX-101 is the culmination of over 20 years of scientific research to understand the challenges faced by patients with progressive disease after hematopoietic stem cell transplantation, the current standard of care,” said Maria Escolar, M.D., Forge’s Chief Medical Officer. “We are currently recruiting patients for our RESKUE clinical trial to administer FBX-101 and we are pleased by the EMA’s designation so that patients in Europe may also have access to this potentially transformative therapeutic approach.”
The company also announced that the FDA has provided positive feedback on Forge’s AAV manufacturing processes, including use of its exclusive production plasmids and master cell bank for cGMP manufacturing of gene therapies.
Forge presented information to the FDA on its proprietary HEK293 suspension cell line, Ignition Cells™, and adenovirus helper plasmid, pEMBR™, and received FDA alignment that these technologies are suitable for cGMP manufacturing of clinical drug products.
“We are excited that the tools we have developed at Forge will help accelerate and scale cGMP production of AAV gene therapies for patients. We are thankful to have a positive dialogue with the EMA and for gaining alignment with the FDA on the suitability of our key production materials for our own and our clients’ use,” said Christopher Shilling, Vice President of Regulatory Affairs and Quality. “These new technologies can help mitigate current safety concerns surrounding critical raw materials used in AAV scale-up and production processes for programs moving from research to clinical stage.”
Forge offers “concept to clinic” AAV manufacturing and development services to accelerate gene therapy programs from preclinical stage through clinical with technology platforms enabling fully traceable cell line history for potential commercialization.
About Krabbe Disease
Krabbe disease is a rare, pediatric leukodystrophy affecting about 1-2.5 in 100,000 people in the U.S. and is inherited in an autosomal recessive manner. Krabbe disease is caused by loss-of-function mutations in the galactosylceramidase (GALC) gene, a lysosomal enzyme responsible for the breakdown of certain types of lipids such as psychosine. Without functional GALC, psychosine accumulates to toxic levels in cells. The psychosine toxicity is most severe in the myelin cells surrounding the nerves in the brain and in the peripheral nervous system, eventually leading to the death of these cells. The disease initially manifests as physical delays in development, muscle weakness and irritability and advances rapidly to difficulty swallowing, breathing and cognitive problems, and vision and hearing loss. Early onset or “Infantile” Krabbe disease cases usually results in death of patients by age 2-4 years, while later onset or “Late Infantile” cases have a more variable course of progressive decline. There is currently no approved treatment for Krabbe disease.
Forge developed FBX-101 to treat patients with Infantile Krabbe disease. FBX-101 is an adeno-associated viral (AAV) gene therapy that is typically delivered after a hematopoietic stem cell transplant. FBX-101 delivers a functional copy of the GALC gene to cells in both the central and peripheral nervous system. FBX-101 has been shown to functionally correct the central and peripheral neuropathy and correct the behavioral impairments associated with Krabbe disease in animal models, as well as to drastically improve lifespan in animal models of the disease. This approach has the potential to overcome some of the immunological safety challenges observed in traditional AAV gene therapies.
About Orphan Designation
EMA orphan designation is designed to encourage the development of new treatments for life-threatening or chronically debilitating conditions that are rare (affecting not more than five in 10,000 people in the European Union). Medicines like FBX-101 that meet the EMA’s orphan designation criteria qualify for several incentives, including extended market exclusivity, protocol assistance, and potentially reduced fees for regulatory activities. The orphan designation is issued by the EMA Committee for Orphan Medicinal Products (COMP) for use in the European Union.
About Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea into reality. Forge has a 175,000 square foot facility in Columbus, Ohio, The Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.
For more information, please visit https://www.forgebiologics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Senior Manager, Marketing and Communications
Families and Clinician Inquiries
Dr. Maria Escolar
Chief Medical Officer
Vice President and Head, Business Development
Chief Commercial Officer
Christina Perry, MSA, CPA
Vice President, Finance and Investor Relations
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Janssen Receives Positive CHMP Opinion for RYBREVANT® (amivantamab) for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations After Failure of Platinum-Based Therapy15.10.2021 19:30:00 EEST | Press release
FOR EU TRADE AND MEDICAL MEDIA ONLY. NOT TO BE DISTRIBUTED TO UK AND BENELUX BASED MEDIA The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product amivantamab, intended for the treatment of adult patients with advanced NSCLC with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations, after failure of platinum-based therapy.3 If approved, amivantamab will be the first treatment in the European Union specifically targeting EGFR exon 20 insertion mutations for advanced NSCLC.1 “This group of patients often face a poor prognosis as there are currently no targeted therapy options for this specific mutation nor does it typically respond to existing therapies used to treat more common EGFR mutations,” 1,4,5 commented Catherine Taylor, M.D., Vice President, Medical Affairs
Leading Researchers Present 24-Plex Digital PCR Assay and Novel Multiplex Applications Uniquely Enabled by Stilla’s 6-Color naica® system15.10.2021 16:08:00 EEST | Press release
Stilla Technologies, the multiplex digital PCR company, joined researchers from SAGA Diagnostics in presenting a 24-plex digital PCR assay generated on Stilla’s six-color naica® system. To mark the platform’s global commercial launch at the American Society of Human Genetics (ASHG) 2021 Virtual Meeting, Stilla’s Cofounder and Chief Technology Officer Rémi Dangla, PhD, and researchers from SAGA Diagnostics, Fred Hutchinson Cancer Research Center, and University of Athens highlighted the new data during a discussion on how highly sensitive, multiplex digital PCR technology is transforming complex genomic data into actionable insights across a breadth of research and clinical applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211015005140/en/ Stilla’s six-color naica® system, the industry’s first six-color digital PCR system, answers market needs for higher performance and multiplexing technology. Learn more here: www
Boston Metal Wins S&P Global Platts Global Metals Award15.10.2021 16:04:00 EEST | Press release
Boston Metal won the New Technology for the Metals and Mining Industry award at the 2021 S&P Global Platts Global Metals Awards. Boston Metal is commercializing ground-breaking technology to decarbonize primary steelmaking. The company’s technology combines patented innovations with best practices from the aluminum and steel industries to deliver a revolutionary solution to the carbon emissions challenge facing the steel value chain. Powered by renewable electricity, molten oxide electrolysis converts iron ore into liquid metal and oxygen. The modular, scalable platform produces no CO2 emissions, is highly energy efficient, and works with a wide range of iron ore grades. “We congratulate all the winners and finalists for persevering through unique challenges and continuing to drive performance while embracing change,” said Saugata Saha, president of S&P Global Platts. Dave Ernsberger, Global Head of Pricing and Market Insight, S&P Global Platts, said: “Not surprisingly, but certainly e
The Ministry of Justice makes public the evidence supporting of the Republic of Kazakhstan’s case against Anatolie and Gabriel Stati15.10.2021 14:46:00 EEST | Press release
The Ministry of Justice has launched a new website to spotlight evidence gathered by the Republic of Kazakhstan regarding the fraud committed by Anatolie and Gabriel Stati: www.kzarbitration.com. The purpose of the website is to present the facts of the ongoing and complex legal case and provide easy access to the corresponding evidence. This public repository will increase transparency around the case and dispel the disinformation and lies perpetrated by these individuals against the Republic of Kazakhstan and its people. The evidence - in the form of court rulings, expert opinions, and other publicly available documents - confirms that the Statis have been engaged in a complex and multi-faceted fraud since at least 2006. The website explains how Anatolie and Gabriel Stati defrauded international investors of their money, falsified financial statements, fraudulently obtained audit opinions and pursued an international arbitration against the Republic of Kazakhstan to recoup from the S
TP Awards Schlumberger Sakarya Offshore Gas Field Phase-1 Contract15.10.2021 14:00:00 EEST | Press release
Schlumberger announced today a significant contract award by Turkish Petroleum (TP) for the engineering, procurement, construction and installation (EPCI) of end-to-end production solutions for the Sakarya gas field, Turkey’s largest gas reserve. The contract is awarded to Schlumberger and Subsea 7, as part of a consortium. The integrated project scope will cover subsurface solutions to onshore production, including well completions, subsea production systems (SPS), subsea umbilicals, risers, flowlines (SURF), and an early production facility (EPF). Schlumberger will deliver the well completions scope and the design, construction, and commissioning of the early production facility capable of handling up to 350 MMscfd of gas. The SPS and SURF scope will be delivered by OneSubsea®, the subsea technologies, production, and processing systems division of Schlumberger, and Subsea 7. “Schlumberger is uniquely positioned to integrate solutions from the subsurface to the processing facility, a
Pony.ai to Start Driverless Tests on Public Roads in Beijing15.10.2021 10:00:00 EEST | Press release
Silicon Valley-based leading autonomous driving company Pony.ai, today announced that it has been authorized to conduct driverless tests on public roads in China’s capital city, Beijing. The company is one of the two autonomous software companies to receive this important Beijing permit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211015005137/en/ Driverless tests on public roads in Beijing (Photo: Business Wire) Prior to receiving this driverless test permit in Beijing, Pony.ai received a permit to conduct tests on certain sections of Beijing highways in July 2021. The company was among the first group to obtain this permit. In Beijing, Pony.ai is now authorized to conduct driverless testing in an area of around 20 square kilometers in a pilot zone for autonomous driving vehicles. The area covers major subway stations, residential areas, and tech parks, which allows Pony.ai to test its autonomous technology in the most c
Announcing the 2021 .eu Web Awards Winners!15.10.2021 10:00:00 EEST | Press release
Last night the 2021 .eu Web Awards ended in epic fashion at the Teatro Antico in Taormina, Italy. Hosted by EURid, the .eu Web Awards are a competition for the best .eu, .ею and .ευ websites. After last year’s virtual only event, we were pleased to once again celebrate the finalists and winners in person. View the hybrid event here. Hosted by Sally Bundock, esteemed journalist for BBC world news, the gala night brought us sincere joy reflected by the winners, combined with amazing performances by featured artists like THePETEBOX, Women Orchestra, MM Dance Company, Compagnia Joculares and the GAP’s Orchestra. The magical event ended with fireworks. “Being able to see real faces and raw emotion conveyed by the guests again made the night unforgettable” noted Giovanni Seppia, EURid’s External Relations Manager. “This is what the Web Awards is all about, bringing together people from various industries and backgrounds and honouring them for having chosen a .eu for their online presence.” P
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom